Vir Biotechnology, Inc. financial data

Symbol
VIR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
1800 Owens Street, Suite 900, San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 4, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.05K % +68.9%
Debt-to-equity 32.3 % -21%
Return On Equity -36.7 % -15.1%
Return On Assets -31 % -25.9%
Operating Margin -775 % -32.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 138M shares +2.38%
Common Stock, Shares, Outstanding 137M shares +1.64%
Entity Public Float 1.8B USD -10%
Common Stock, Value, Issued 14K USD +7.69%
Weighted Average Number of Shares Outstanding, Basic 137M shares +1.76%
Weighted Average Number of Shares Outstanding, Diluted 137M shares +1.76%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 78.6M USD -33.8%
Cost of Revenue 959K USD +31.6%
Research and Development Expense 519M USD -17%
Costs and Expenses 688M USD -15.6%
Operating Income (Loss) -609M USD +12.5%
Nonoperating Income (Expense) 69.8M USD +90.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -539M USD +18.2%
Income Tax Expense (Benefit) -5.84M USD
Net Income (Loss) Attributable to Parent -533M USD +11.2%
Earnings Per Share, Basic -3.92 USD/shares +13.1%
Earnings Per Share, Diluted -3.92 USD/shares +12.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 168M USD -62.8%
Marketable Securities, Current 741M USD -40%
Cash, Cash Equivalents, and Short-term Investments 1.19B USD -30%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Other Assets, Current 0 USD -100%
Assets, Current 1.05B USD -40.8%
Property, Plant and Equipment, Net 64.8M USD -34.8%
Operating Lease, Right-of-Use Asset 60.8M USD -16.3%
Intangible Assets, Net (Excluding Goodwill) 19.3M USD -24.4%
Goodwill 16.9M USD +0.01%
Assets 1.5B USD -26.7%
Accounts Payable, Current 7.31M USD +101%
Liabilities, Current 117M USD -29%
Deferred Income Tax Liabilities, Net 3.25M USD -82.4%
Operating Lease, Liability, Noncurrent 93.4M USD -18.2%
Other Liabilities, Noncurrent 13.9M USD +5.78%
Liabilities 258M USD -30.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.13M USD
Retained Earnings (Accumulated Deficit) -655M USD -438%
Stockholders' Equity Attributable to Parent 1.97B USD -1.51%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 1.24B USD -25.9%
Liabilities and Equity 1.5B USD -26.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -109M USD +13%
Net Cash Provided by (Used in) Financing Activities 152K USD -93.5%
Net Cash Provided by (Used in) Investing Activities 28.4M USD -71%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 137M shares +1.64%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -80.8M USD -219%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 264M USD -44%
Deferred Tax Assets, Valuation Allowance 357M USD +74.4%
Deferred Tax Assets, Gross 250M USD +158%
Operating Lease, Liability 125M USD -2.68%
Depreciation 2.9M USD -35.6%
Payments to Acquire Property, Plant, and Equipment 1.87M USD -72.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -530M USD +10.2%
Lessee, Operating Lease, Liability, to be Paid 156M USD -10.6%
Property, Plant and Equipment, Gross 100M USD -22.5%
Operating Lease, Liability, Current 19.4M USD +43.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 16.5M USD -11.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 18.8M USD -3.35%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 31.9M USD -17%
Lessee, Operating Lease, Liability, to be Paid, Year Three 16.9M USD +3.88%
Deferred Tax Assets, Operating Loss Carryforwards 138M USD +835%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 14.8M USD +14.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 17.1M USD +2.19%
Additional Paid in Capital 1.89B USD +5.33%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 133K USD 0%
Depreciation, Depletion and Amortization 17.8M USD +70%
Share-based Payment Arrangement, Expense 90.9M USD -15.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%